β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation.
G protein-coupled receptor
immunohistochemistry
in vitro analyses
ovarian cancer
survival analysis
β-arrestin 2
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
04
2020
accepted:
12
08
2020
entrez:
12
10
2020
pubmed:
13
10
2020
medline:
27
5
2021
Statut:
epublish
Résumé
Establishing reliable prognostic factors as well as specific targets for new therapeutic approaches is an urgent requirement in advanced ovarian cancer. For several tumor entities, the ubiquitously spread scaffold protein β-arrestin 2, a multifunctional scaffold protein regulating signal transduction and internalization of activated G protein-coupled receptors (GPCRs), has been considered with rising interest for carcinogenesis. Therefore, we aimed to elucidate the prognostic impact of β-arrestin 2 and its functional role in ovarian cancer. β-arrestin 2 expression was analyzed in a subset of 156 samples of ovarian cancer patients by immunohistochemistry. Cytoplasmic expression levels were correlated with clinical as well as pathological characteristics and with prognosis. The biologic impact of β-arrestin 2 on cell proliferation and survival was evaluated,
Identifiants
pubmed: 33042017
doi: 10.3389/fendo.2020.554733
pmc: PMC7530235
doi:
Substances chimiques
ARRB2 protein, human
0
Biomarkers, Tumor
0
Receptors, Gonadotropin
0
beta-Arrestin 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
554733Informations de copyright
Copyright © 2020 Czogalla, Partenheimer, Jeschke, von Schönfeldt, Mayr, Mahner, Burges, Simoni, Melli, Benevelli, Bertini, Casarini and Trillsch.
Références
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11
pubmed: 19202075
Mol Cell Endocrinol. 2019 Feb 15;482:37-44
pubmed: 30543878
J Ovarian Res. 2013 Jan 22;6(1):6
pubmed: 23339713
BMC Cancer. 2012 Jan 03;12:2
pubmed: 22214378
Oncogene. 2017 Oct 12;36(41):5734-5744
pubmed: 28581517
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1354-63
pubmed: 25973019
Obstet Gynecol. 1990 Feb;75(2):263-73
pubmed: 2300355
Mol Hum Reprod. 2017 Oct 1;23(10):685-697
pubmed: 29044421
BMC Res Notes. 2012 Oct 05;5:551
pubmed: 23036050
Sci Rep. 2017 Apr 19;7(1):940
pubmed: 28424471
Front Endocrinol (Lausanne). 2019 Jul 24;10:503
pubmed: 31396162
Eur J Cell Biol. 2018 Jun;97(5):349-358
pubmed: 29665971
Endocr Relat Cancer. 2009 Jun;16(2):599-611
pubmed: 19153210
J Ovarian Res. 2013 Jul 13;6(1):51
pubmed: 23849542
J Immunol. 2008 Apr 15;180(8):5699-706
pubmed: 18390755
Carcinogenesis. 2019 Nov 25;40(11):1395-1404
pubmed: 30923807
Trends Pharmacol Sci. 2011 Sep;32(9):521-33
pubmed: 21680031
Pharmacol Rev. 2017 Jul;69(3):256-297
pubmed: 28626043
Expert Opin Pharmacother. 2017 Oct;18(14):1443-1455
pubmed: 28521614
Cancer Lett. 2019 Jul 10;454:224-233
pubmed: 31004703
Gynecol Oncol. 2006 Jan;100(1):33-7
pubmed: 16153692
Obstet Gynecol. 2012 Sep;120(3):612-8
pubmed: 22914471
J Biol Chem. 2011 Jun 24;286(25):22441-55
pubmed: 21540189
J Clin Endocrinol Metab. 1994 Mar;78(3):705-10
pubmed: 8126145
Curr Opin Cell Biol. 2014 Apr;27:63-71
pubmed: 24680432
Breast Cancer Res Treat. 2011 Jul;128(2):457-66
pubmed: 21607586
Cell Death Dis. 2016 Apr 07;7:e2183
pubmed: 27054338
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Sci Rep. 2016 May 03;6:25408
pubmed: 27139372
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int Rev Cell Mol Biol. 2019;346:129-155
pubmed: 31122393
Reprod Biomed Online. 2019 May;38(5):816-824
pubmed: 30910395
Int J Mol Sci. 2019 Jun 12;20(12):
pubmed: 31212758
Int J Mol Sci. 2017 Apr 28;18(5):
pubmed: 28452938
Biochemistry. 2019 Feb 12;58(6):799-808
pubmed: 30532959
Front Endocrinol (Lausanne). 2015 Aug 27;6:130
pubmed: 26379624
Cancer Res. 2019 Sep 1;79(17):4439-4452
pubmed: 31273063
Trends Endocrinol Metab. 2018 Apr;29(4):208-217
pubmed: 29429918
BMC Cancer. 2012 Dec 28;12:624
pubmed: 23273253
Front Endocrinol (Lausanne). 2019 Feb 04;10:32
pubmed: 30778333
Mol Clin Oncol. 2016 Mar;4(3):399-404
pubmed: 26998291
Cancer Res. 2005 Dec 15;65(24):11649-57
pubmed: 16357176
Mol Cell Endocrinol. 2016 Dec 5;437:11-21
pubmed: 27502035
Cell. 2016 Aug 11;166(4):907-919
pubmed: 27499021
Proc Natl Acad Sci U S A. 2009 May 19;106(20):8221-6
pubmed: 19416857
EMBO J. 2002 Aug 1;21(15):4037-48
pubmed: 12145204
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1492-7
pubmed: 16432186
J Natl Cancer Inst. 2011 Feb 16;103(4):317-33
pubmed: 21212384
Reprod Sci. 2012 Nov;19(11):1197-204
pubmed: 22573494
Int J Mol Sci. 2019 Nov 07;20(22):
pubmed: 31703269
Arch Med Res. 1999 Nov-Dec;30(6):501-9
pubmed: 10714364
Mol Cell Endocrinol. 2009 Mar 5;300(1-2):164-8
pubmed: 19007852
Int J Mol Med. 2018 Feb;41(2):631-639
pubmed: 29207104
Endocrinology. 1983 Sep;113(3):1176-8
pubmed: 6191970
Annu Rev Physiol. 2007;69:483-510
pubmed: 17305471
Lancet. 2001 Jan 20;357(9251):176-82
pubmed: 11213094
Methods Mol Biol. 2018;1709:107-127
pubmed: 29177655
Mol Cancer Res. 2009 Jul;7(7):1064-77
pubmed: 19609003
Cancer Res. 2008 Jun 1;68(11):4097-104
pubmed: 18519668
PLoS One. 2013 Aug 09;8(8):e71791
pubmed: 23951246
PLoS One. 2012;7(10):e46682
pubmed: 23071612
Pathobiology. 2018;85(1-2):41-49
pubmed: 29020678